Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Arthritis Research & Therapy|September 13, 2008
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusRichard Furie, William Stohl, Ellen M Ginzler, et al.
Journal of the American Society of Nephrology : JASN|April 17, 2009
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritisGerald B Appel, Gabriel Contreras, Mary Anne Dooley, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 11, 2012
Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?Brad H Rovin, Samir V Parikh, Lee A Hebert, et al.
Arthritis and Rheumatism|July 19, 2002
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trialMichelle A Petri, Robert G Lahita, Ronald F Van Vollenhoven, et al.
Kidney International|November 14, 1997
Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA allelesL A Haseley, J J Wisnieski, M R Denburg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2021
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal ToxicityJames T Rosenbaum, Karen H Costenbader, Julianna Desmarais, et al.
The New England Journal of Medicine|November 25, 2005
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler, Mary Anne Dooley, Cynthia Aranow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 26, 2021
American College of Rheumatology White Paper on Antimalarial Cardiac ToxicityJulianna Desmarais, James T Rosenbaum, Karen H Costenbader, et al.
Arthritis and Rheumatism|August 29, 2009
Novel evidence-based systemic lupus erythematosus responder indexRichard A Furie, Michelle A Petri, Daniel J Wallace, et al.
Arthritis and Rheumatism|June 8, 2012
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosusJoan T Merrill, Ellen M Ginzler, Daniel J Wallace, et al.
Pageof 13